Diabetes impairs left ventricular systolic and diastolic function and is associated with a number of abnormalities at the cellular level in the various steps of excitation-contraction coupling and signaling pathways. Two key abnormalities in experimental diabetic cardiomyopathy are a defect in sarcoplasmic reticulum (SR) function, which is associated with abnormal intracellular calcium handling, and a reduction in phosphatidyl-inositol 3-OH (PI3-) kinase activity and GLUT-4 expression. Deficient SR Ca2+ uptake during relaxation has been identified in diabetic hearts and has been associated with a decrease in the expression and activity of SR Ca2+-ATPase (SERCA2a). Furthermore, a decrease in PI3 kinase activity leading to a decrease in Akt activation and subsequently a decrease in GLUT-4 expression leads to impaired glucose uptake and hypertrophy. Using gene transfer to target specific pathways in cardio-myocytes, we will try to understand whether the excitation-contraction coupling changes in diabetic hearts occur before overt heart failure develops and/or participate in the initiation or the worsening of the changes. We will test the following hypotheses: 1) that the decrease in PI3-Kinase activity is linked to the EC coupling pathways and so contributes to the contractile dysfunction in diabetic hearts: 2) that metabolic interventions will protect against cardiac contractile dysfunction in diabetic hearts: and 3) that modulation of insulin-mediated signal transduction pathways in vivo can favorably modulate alterations of the EC coupling pathways and improve cardiac energetics and survival in diabetic rats. To test these hypotheses, we will use viral vectors to express wild-type and mutant forms of specific signaling molecules in cardiomyocytes in vitro and in vivo. We will examine the effects of PI3-Kinase, Akt, and GLUT-4 on contractile function, energetics and survival and remodeling in diabetic cardiomyopathic hearts. Animal models of type 1 and type 2 diabetes will be utilized in addition to primary cultures of human and adult rats ventricular myocytes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL078731-04
Application #
7821183
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Liang, Isabella Y
Project Start
2007-05-15
Project End
2011-04-30
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
4
Fiscal Year
2010
Total Cost
$423,750
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Chen, Jiqiu; Hammoudi, Nadjib; Benard, Ludovic et al. (2016) The Probability of Inconstancy in Assessment of Cardiac Function Post-Myocardial Infarction in Mice. Cardiovasc Pharm Open Access 5:
Karakikes, Ioannis; Hadri, Lahouaria; Rapti, Kleopatra et al. (2012) Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther 20:565-71
Kho, Changwon; Lee, Ahyoung; Hajjar, Roger J (2012) Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol 9:717-33
Hulot, Jean-Sébastien; Fauconnier, Jérémy; Ramanujam, Deepak et al. (2011) Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation 124:796-805
Kho, Changwon; Lee, Ahyoung; Jeong, Dongtak et al. (2011) SUMO1-dependent modulation of SERCA2a in heart failure. Nature 477:601-5
Dhandapany, Perundurai S; Fabris, Frank; Tonk, Rahul et al. (2011) Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol 51:4-15
Kawase, Yoshiaki; Ladage, Dennis; Hajjar, Roger J (2011) Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol 57:1169-80
Jessup, Mariell; Greenberg, Barry; Mancini, Donna et al. (2011) Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124:304-13
Gwathmey, Judith K; Yerevanian, Alexan I; Hajjar, Roger J (2011) Cardiac gene therapy with SERCA2a: from bench to bedside. J Mol Cell Cardiol 50:803-12
Ladage, D; Turnbull, I C; Ishikawa, K et al. (2011) Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model. Gene Ther 18:979-85

Showing the most recent 10 out of 18 publications